Spurr et al. identify high pretreatment aneuploidy score as a potential biomarker in patients with NSCLC who benefit from concurrent radiation and immune checkpoint inhibition, in immunogenomic analysis of data from a phase I clinical trial.
- Liam F. Spurr
- Carlos A. Martinez
- Sean P. Pitroda